AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12744364 — intervention group
Group type: COMPARATOR
Intervention: Intraventricular vancomycin (10 mg once daily)
Number of subjects: 10
Study 11168190 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants (EG)
Number of subjects: 22
Study 11168190 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-stage protocol (CG)
Number of subjects: 22
Study 11168190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EG and CG)
Number of subjects: 22
Study 8997652 — intervention group
Group type: EXPERIMENTAL
Intervention: Salifluor combined with PVM/MA copolymer and NaF in mouthrinse and dentifrice formulations.
Number of subjects: 0
Study 8997652 — intervention group
Group type: EXPERIMENTAL
Intervention: Non fluoride dentifrice containing salifluor and PVM/MA copolymer with dicalcium phosphate dihydrate abrasive.
Number of subjects: 0
Study 1443440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation for 6 weeks
Number of subjects: 49
Study 1443440 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 49
Study 6728584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Home Care (PHC) program
Number of subjects: 219
Study 30266581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid (OA)
Number of subjects: 20
Study 30266581 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 20
Study 30266581 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 20
Study 30266581 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged men
Number of subjects: 20
Study 29562659 — intervention group
Group type: EXPERIMENTAL
Intervention: Three energy drinks (EDs) consumed at one-hour intervals (240 mg of caffeine total)
Number of subjects: 68
Study 29562659 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 68
Study 27087449 — intervention group
Group type: EXPERIMENTAL
Intervention: SEED 1dayPure moisture contact lenses with alginic acid (n = 15)
Number of subjects: 30
Study 27087449 — intervention group
Group type: COMPARATOR
Intervention: SEED 1dayPure moisture contact lenses without alginic acid (n = 15)
Number of subjects: 30
Study 25304296 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic-type diet
Number of subjects: 34
Study 25304296 — intervention group
Group type: COMPARATOR
Intervention: Healthy reference diet
Number of subjects: 34
Study 22405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg and pioglitazone 30 mg (base study)
Number of subjects: 520
Study 22405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg and pioglitazone 45 mg (extension study)
Number of subjects: 520
Study 22405352 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy (30 mg)
Number of subjects: 520
Study 22405352 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy (45 mg)
Number of subjects: 520
Study 21337796 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Number of subjects: 30
Study 19227591 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a validated prognostic score for mortality risk
Number of subjects: 68
Study 19227591 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 68
Study 15664241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100mg/day
Number of subjects: 76
Study 12017407 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (insulin LP)
Number of subjects: 481
Study 12017407 — intervention group
Group type: COMPARATOR
Intervention: Insulin R
Number of subjects: 481
Study 10394005 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment with monotherapy on an outpatient basis
Number of subjects: 0
Study 7580637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetic therapy
Number of subjects: 70
Study 7580637 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetic therapy
Number of subjects: 70
Study 2290653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 0
Study 2290653 — intervention group
Group type: EXPERIMENTAL
Intervention: T.E.R.M.
Number of subjects: 0
Study 2290653 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6766731 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol 200 mg twice daily
Number of subjects: 13
Study 6766731 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol 400 mg once daily
Number of subjects: 13
Study 6766731 — intervention group
Group type: COMPARATOR
Intervention: acebutolol (both dosages)
Number of subjects: 13
Study 6766731 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 31099869 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (CNN)
Number of subjects: 3082
Study 31099869 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (CNN) applied to colonoscopy videos
Number of subjects: 3082
Study 31099869 — intervention group
Group type: COMPARATOR
Intervention: Experienced human reviewers
Number of subjects: 3082
Study 27647784 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided heart failure management (Treatment group)
Number of subjects: 0
Study 27647784 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 0
Study 26281946 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (manual therapies including desensitization maneuvers), n = 60
Number of subjects: 120
Study 26281946 — intervention group
Group type: COMPARATOR
Intervention: Surgery (decompression/release of the carpal tunnel), n = 60
Number of subjects: 120
Study 24293754 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP)
Number of subjects: 366
Study 24293754 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 366
Study 24293754 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective HRP
Number of subjects: 366
Study 24293754 — intervention group
Group type: COMPARATOR
Intervention: Home respiratory polygraphy (HRP) for all patients
Number of subjects: 366
Study 24293754 — intervention group
Group type: COMPARATOR
Intervention: Home respiratory polygraphy (HRP) for symptomatic patients and PSG for the rest
Number of subjects: 366
Study 20977487 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer pamphlet providing descriptions of common causes of anemia and advice for seeking medical attention
Number of subjects: 104
Study 20977487 — intervention group
Group type: COMPARATOR
Intervention: Older pamphlet providing a list of iron‐rich foods
Number of subjects: 104
Study 20977487 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood center practices for care of donors with low Hct
Number of subjects: 104
Study 20977487 — intervention group
Group type: EXPERIMENTAL
Intervention: Study of donors with low Hct
Number of subjects: 104
Study 20035395 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-DEHP bilayer group (group B)
Number of subjects: 16
Study 20035395 — intervention group
Group type: COMPARATOR
Intervention: Noncoated PVC group (group N)
Number of subjects: 16
Study 17122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation (10 mg/d for 6 months)
Number of subjects: 45
Study 14506371 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 433
Study 14506371 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine
Number of subjects: 433
Study 11060137 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 % CHO beverage
Number of subjects: 0
Study 11060137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11060137 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion
Number of subjects: 0
Study 9382020 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimyosin imaging
Number of subjects: 7
Study 8285950 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol in combination with ketamine 20 mg
Number of subjects: 200
Study 8285950 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol in combination with fentanyl 0.1 mg
Number of subjects: 200
Study 8285950 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopentone in combination with fentanyl 0.1 mg
Number of subjects: 200
Study 8285950 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexitone in combination with fentanyl 0.1 mg
Number of subjects: 200
Study 3929874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 183
Study 3929874 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 183
Study 30303626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemiralisib (200, 500, and 700 μg)
Number of subjects: 36
Study 30303626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Number of subjects: 36
Study 30303626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29126244 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT (carboplatin/paclitaxel with 41.4-Gy radiotherapy) plus surgery
Number of subjects: 368
Study 29126244 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 368
Study 29126244 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT plus surgery
Number of subjects: 368
Study 27025777 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drainage (DG)
Number of subjects: 62
Study 27025777 — intervention group
Group type: COMPARATOR
Intervention: No drainage group (NDG)
Number of subjects: 62
Study 25191771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 18
Study 25191771 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 25191771 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 18
Study 22079178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention for weight loss maintenance
Number of subjects: 932
Study 19268926 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching performed by acidic Tyrode's solution
Number of subjects: 121
Study 19268926 — intervention group
Group type: COMPARATOR
Intervention: No procedure (unhatched)
Number of subjects: 121
Study 17301956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (18.7 mg/kg for patients < 12 kg, 560 mg/m(2) for patients >/= 12 kg)
Number of subjects: 25
Study 17301956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin
Number of subjects: 25
Study 16204601 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification
Number of subjects: 70
Study 16204601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no heated humidification)
Number of subjects: 70
Study 12365851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active responding in matched condition
Number of subjects: 4
Study 12365851 — intervention group
Group type: COMPARATOR
Intervention: Non-matched condition
Number of subjects: 4
Study 12365851 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tasks
Number of subjects: 4
Study 12365851 — intervention group
Group type: COMPARATOR
Intervention: Active tasks
Number of subjects: 4
Study 12451320 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (n = 10)
Number of subjects: 20
Study 12451320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 9732929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate plus magnesium citrate (SPS‐Mg)
Number of subjects: 68
Study 9732929 — intervention group
Group type: COMPARATOR
Intervention: Sulphate-free polyethylene glycol electrolyte lavage (PEG‐EL)
Number of subjects: 68
Study 8060692 — intervention group
Group type: EXPERIMENTAL
Intervention: Molloplast-b (silicone-based)
Number of subjects: 44
Study 8060692 — intervention group
Group type: COMPARATOR
Intervention: Palasiv 62 (heat-cured plasticised acrylic)
Number of subjects: 44
Study 8060692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 44
Study 2972162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17 beta‐estradiol cyclo‐octyl acetate (E2COA) + 0.15 mg desogestrel
Number of subjects: 8
Study 2972162 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta‐estradiol (mE2) + 0.15 mg desogestrel
Number of subjects: 8
Study 29856312 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychological care (EPC)
Number of subjects: 29
Study 29856312 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation care (UC)
Number of subjects: 29
Study 28115329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo normothermic perfusion (EVNP)
Number of subjects: 400
Study 28115329 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage
Number of subjects: 400
Study 24378148 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-cranking exercise (12 weeks, 3 sessions/week)
Number of subjects: 17
Study 23298985 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings Are Special (SIBS) program
Number of subjects: 174
Study 23298985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 174
Study 21467235 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CoQ(10) levels
Number of subjects: 993
Study 17429754 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol (progressive doses of Dobutamine with early atropine administration)
Number of subjects: 168
Study 17429754 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (progressive doses of Dobutamine with late atropine administration)
Number of subjects: 168
Study 17429754 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol
Number of subjects: 168
Study 17429754 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 168
Study 17429754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 168
Study 16493215 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic resection (PK)
Number of subjects: 48
Study 16493215 — intervention group
Group type: COMPARATOR
Intervention: Standard monopolar TURP
Number of subjects: 48
Study 12943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 28
Study 12943958 — intervention group
Group type: COMPARATOR
Intervention: Classical mood stabilizers
Number of subjects: 28
Study 11131082 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice gerontological nurses (APNs)
Number of subjects: 197
Study 11131082 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study 9364249 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 34
Study 9364249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick/normal FTI
Number of subjects: 34
Study 9364249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick/low FTI
Number of subjects: 34
Study 1494189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% with epinephrine (Group I)
Number of subjects: 0
Study 1494189 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (Group II)
Number of subjects: 0
Study 1494189 — intervention group
Group type: COMPARATOR
Intervention: No injections (Group III, Control)
Number of subjects: 0
Study 30858305 — intervention group
Group type: EXPERIMENTAL
Intervention: WISENSE
Number of subjects: 324
Study 30858305 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 324
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive parenting
Number of subjects: 421
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 421
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction
Number of subjects: 421
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritarian parenting
Number of subjects: 421
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring child dietary intake
Number of subjects: 421
Study 27940314 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of child dietary intake
Number of subjects: 421
Study 26002807 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARCs)
Number of subjects: 987
Study 26002807 — intervention group
Group type: EXPERIMENTAL
Intervention: Other prescription methods (primarily oral contraceptives)
Number of subjects: 987
Study 26002807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription methods (primarily condoms)
Number of subjects: 987
Study 26002807 — intervention group
Group type: EXPERIMENTAL
Intervention: No method
Number of subjects: 987
Study 23103177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (600 mg, about 13 mg/kg) intravenously
Number of subjects: 60
Study 23103177 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rifampicin (450 mg, about 10 mg/kg) orally
Number of subjects: 60
Study 23103177 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 800 mg once daily
Number of subjects: 60
Study 23103177 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily
Number of subjects: 60
Study 23103177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol 750 mg once daily
Number of subjects: 60
Study 23103177 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose isoniazid, pyrazinamide, and adjunctive corticosteroids
Number of subjects: 60
Study 21402649 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group engaged in standing, static balancing, and mild leg exercise 12 minutes per session, three times per week for 12 weeks
Number of subjects: 25
Study 21402649 — intervention group
Group type: COMPARATOR
Intervention: Control group given literature on prevention of falls
Number of subjects: 25
Study 18805656 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine-naloxone
Number of subjects: 344
Study 18805656 — intervention group
Group type: COMPARATOR
Intervention: clonidine
Number of subjects: 344
Study 18805656 — intervention group
Group type: EXPERIMENTAL
Intervention: inpatient setting
Number of subjects: 344
Study 18805656 — intervention group
Group type: EXPERIMENTAL
Intervention: tobacco use
Number of subjects: 344
Study 18805656 — intervention group
Group type: EXPERIMENTAL
Intervention: severe baseline anxiety symptoms
Number of subjects: 344
Study 16682586 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular grid laser photocoagulation after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 74
Study 16682586 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) only
Number of subjects: 74
Study 16682586 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular grid laser photocoagulation after IVTA
Number of subjects: 74
Study 15498091 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO definition of metabolic syndrome
Number of subjects: 917
Study 15498091 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP definition of metabolic syndrome
Number of subjects: 917
Study 15498091 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WHO and NCEP definitions
Number of subjects: 917
Study 15498091 — intervention group
Group type: COMPARATOR
Intervention: Mean values of waist circumference, BMI, triglycerides, HDL cholesterol
Number of subjects: 917
Study 11729015 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused psychotherapy
Number of subjects: 30
Study 11729015 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy
Number of subjects: 30
Study 11729015 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study 11729015 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 30
Study 9387944 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (400 mg x day(-1))
Number of subjects: 17
Study 9387944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8203989 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher for a free screening mammogram
Number of subjects: 119
Study 8203989 — intervention group
Group type: COMPARATOR
Intervention: No voucher for screening mammogram
Number of subjects: 119
Study 3669768 — intervention group
Group type: COMPARATOR
Intervention: High dose CVP (cyclophosphamide 1500 mg/m2 i.v. day 1, vincristine 1.4 mg/m2 day 1, and prednisone 40 mg/m2 orally days 1‐10)
Number of subjects: 93
Study 3669768 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CAVP (cyclophosphamide 1000 mg/m2 i.v. day 1, doxorubicin 45 mg/m2 i.v. day 1, vincristine and prednisone as above)
Number of subjects: 93
Study 3669768 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CAVP
Number of subjects: 93
Study 3669768 — intervention group
Group type: COMPARATOR
Intervention: High dose CVP and CAVP
Number of subjects: 93
Study 29307683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg regularly twice per week for 3 months immediately after urethral catheter removal
Number of subjects: 120
Study 29307683 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with sildenafil starting 3 months after surgery
Number of subjects: 120
Study 27614077 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 934
Study 23873981 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for GPs
Number of subjects: 49
Study 23150906 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care dedicated inpatient rehabilitation (PCDIR)
Number of subjects: 302
Study 23150906 — intervention group
Group type: COMPARATOR
Intervention: Primary care nursing home rehabilitation (PCNHR)
Number of subjects: 302
Study 23150906 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDIR
Number of subjects: 302
Study 21423852 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ 500 mg twice a day for 7 days
Number of subjects: 270
Study 21423852 — intervention group
Group type: COMPARATOR
Intervention: MTZ 2-gm single dose
Number of subjects: 270
Study 18278532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 120
Study 18278532 — intervention group
Group type: COMPARATOR
Intervention: Best supportive therapy (control)
Number of subjects: 120
Study 16271721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 0